-
1 Comment
NovaBay Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 23.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
NovaBay Pharmaceuticals, Inc's total revenue rose by 10.8% to $2M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-2K since the same quarter in the previous year.
Finally, its free cash flow fell by 1.6% to $-1M since the same quarter in the previous year.
Based on the above factors, NovaBay Pharmaceuticals, Inc gets an overall score of 3/5.
| Exchange | NYSE MKT |
|---|---|
| CurrencyCode | USD |
| ISIN | US66987P2011 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 0.85 |
|---|---|
| Beta | 0.41 |
| PE Ratio | 0.02 |
| Market Cap | 3M |
| Dividend Yield | None |
NovaBay Pharmaceuticals, Inc. does not have significant operations. Previously, the company was engaged in the development and sale of eyecare, wound care, and skin care products in the United States and internationally. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NBY using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
